Literature DB >> 21744340

Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.

Sophia Hl George1, James Greenaway, Anca Milea, Victoria Clary, Sanjeev Shaw, Monika Sharma, Carl Virtanen, Patricia A Shaw.   

Abstract

The discovery of occult invasive and intra-epithelial tubal carcinomas in BRCA1 mutation carriers undergoing prophylactic surgery has implicated the fallopian tube epithelium as the source of serous cancer. However, little is known of the early molecular events of serous oncogenesis, or why cancers in BRCA1 mutation carriers are found preferentially in tissues which are responsive to reproductive hormones. We hypothesize that molecular alterations present in morphologically normal tubal epithelium from BRCA1 heterozygotes reflect the earliest events in serous carcinogenesis and may be markers of increased cancer risk as well as targets for risk reduction. Genetic profiling of microdissected tubal epithelium from histologically normal BRCA1 mutation carriers and controls was performed. We sought to define a signature which differentiated BRCA1 mutant tubal epithelium from women with low risk of developing ovarian cancer. Molecular differences between the follicular and luteal phases were prominent and, by using filtering techniques and a two-way ANOVA without a False Discovery Rate correction, we identified 440 probe sets with a more than two-fold change in gene expression related to BRCA1 mutation status. Using gene ontology and known associations to cancer pathways, we selected five genes for further analysis by qPCR and immunohistochemistry, and were able to demonstrate statistically significant differentiation of BRCA1 and control cases in an independent set of cases. The altered expression profiles in histologically normal tubal epithelium from BRCA1 heterozygotes suggest that these cells may respond differently to microenvironmental stresses.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21744340     DOI: 10.1002/path.2927

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

Review 1.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

2.  Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen Abushahin; Cynthia Laughren; Wenxin Zheng; Setsuko K Chambers
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

3.  Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis.

Authors:  S H L George; A Milea; R Sowamber; R Chehade; A Tone; P A Shaw
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

4.  STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Authors:  Uksha Saini; Adrian A Suarez; Shan Naidu; John J Wallbillich; Kristin Bixel; Ross A Wanner; Jason Bice; Raleigh D Kladney; Jenny Lester; Beth Y Karlan; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2018-01-16       Impact factor: 12.701

5.  Differential expression of extracellular matrix components in the Fallopian tubes throughout the menstrual cycle.

Authors:  Patricia S Diaz; Paula A Solar; Natalia E Juica; Pedro A Orihuela; Hugo Cardenas; Myron Christodoulides; Renato Vargas; Luis A Velasquez
Journal:  Reprod Biol Endocrinol       Date:  2012-08-16       Impact factor: 5.211

Review 6.  The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin.

Authors:  Mirjana Kessler; Christina Fotopoulou; Thomas Meyer
Journal:  Int J Mol Sci       Date:  2013-03-25       Impact factor: 5.923

7.  Impact of the menstrual cycle and ethinyl estradiol/etonogestrel contraceptive vaginal ring on granulysin and other mucosal immune mediators.

Authors:  Sean M Hughes; Urvashi Pandey; Christine Johnston; Jeanne Marrazzo; Florian Hladik; Elizabeth Micks
Journal:  Am J Reprod Immunol       Date:  2021-03-16       Impact factor: 3.777

Review 8.  Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.

Authors:  Jerry Vriend; Mark W Nachtigal
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

Review 9.  BRCA and Early Events in the Development of Serous Ovarian Cancer.

Authors:  Sophia H L George; Patricia Shaw
Journal:  Front Oncol       Date:  2014-01-23       Impact factor: 6.244

10.  Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes.

Authors:  Melissa A Merritt; Stefan Bentink; Matthew Schwede; Marcin P Iwanicki; John Quackenbush; Terri Woo; Elin S Agoston; Ferenc Reinhardt; Christopher P Crum; Ross S Berkowitz; Samuel C Mok; Abigail E Witt; Michelle A Jones; Bin Wang; Tan A Ince
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.